Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer - the ETOP NICOLAS trial
Clinical efficacy of ionizing radiation is usually attributed to induced DNA damage, resulting in direct tumour cell death. The existence of radiation-induced immune mechanisms of tumour control have been described in preclinical models [1]. In the clinical setting, it has been postulated that local radiotherapy could promote local and systemic anti-cancer immune response inducing a phenomenon called “immunogenic cell death” amongst other mechanisms and suggesting that mobilization of antitumour immunity might be a determinant of the overall clinical efficacy of RT on targeted and distant tumours [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A.C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R.A. Stahel, J. Source Type: research